Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – GB1275 granted Orphan Drug Designation for the treatment of pancreatic cancer by the U.S. Food and Drug Administration – Preclinical data for GB1275 featured as cover article in July 3rd edition of Science Translational Medicine – SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company, today announced that it has entered into a clinica

Program addresses aggressive cancers with RTK (HER2, ERBB3, FGFR1, FGFR2) and KRAS mutations SAN DIEGO, November 5, 2019 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the dosing of the first subject in the phase 1/2 study of zotatifin (eFT226) being developed for advanced solid tumor malignancies. Zotatifin is a novel, potent and selective small molecule inhibitor of eukaryoti

EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced data on novel shared tumor-specific neoantigens (TSNA) arising from recurrent cancer driver mutations that have been identified by its EDGE platform. These functionally important gene alterations recurrently observed in cancer patients have